European Medicines Agency (EMA) Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review
Tuesday, May 28, 2019 | DrugName : trastuzumab biosimilar Prestige BioPharma (herein, Prestige) announced that European Medicines Agency (EMA) has
Read More